Chromosome 7q35 and susceptibility to diabetic microvascular complications

被引:28
作者
Patel, A [1 ]
Hibberd, ML [1 ]
Millward, BA [1 ]
Demaine, AG [1 ]
机构
[1] UNIV PLYMOUTH, FAC POSTGRAD MED, DEPT MED, PLYMOUTH PL4 8AA, DEVON, ENGLAND
关键词
ALDOSE REDUCTASE-ACTIVITY; T-CELL RECEPTOR; BETA-CHAIN POLYMORPHISMS; GENE; NEPHROPATHY; NEUROPATHY; INHIBITOR; MELLITUS; CLONING; RATS;
D O I
10.1016/1056-8727(95)00004-6
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Aldose reductase (ALR2), the first enzyme of the polyol pathway, may plan an important role in the pathogenesis of diabetic microvascular complications, The gene coding for ALR2 has been localized to chromosome 7q35. Using an ALR2 probe in conjunction with the restriction endonuclease Bam-HI, we have investigated the ALR2 locus of 128 patients with type I diabetes. A significant decrease in the frequency of the 8.2 kilobase (kb) Bam-HI ALR2 genotype and 8.2 kb allele was found in patients with nephropathy (nephropaths) compared to those with retinopathy alone (retinopaths) (p < 0.05 and 0.25, respectively). We have previously shown that an RFLP of the T-cell antigen receptor constant beta-chain (TCRBC) locus, which is also localized to chromosome 7q35, is strongly associated with susceptibility to microvascular complications. The 128 patients were genotyped using the restriction endonuclease Bgl-II and a TCRBC probe. The 10/9.2-8.2 kb TCRBC-ALR2 genotype was significantly decreased in the nephropaths compared to the retinopaths (13.7% versus 43.6%, chi(2) = 10.1, P < 0,0025). The 10/9.2 and 9.2/9.2 kb TCRBC-ALR2 haplotypes were increased in the nephropaths compared to the retinopaths (32.5% versus 8.9% chi(2) = 10.9, p < 0,001). These results suggest that chromosome 7q35 harbors a gene(s) that is involved in the pathogenesis of microvascular complications. Interestingly, the gene coding for endothelial nitric oxide synthase has recently been localized to the same chromosomal region as ALR2.
引用
收藏
页码:62 / 67
页数:6
相关论文
共 35 条
[1]
ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].
BAYNES, JW .
DIABETES, 1991, 40 (04) :405-412
[2]
PROTEINURIA AND ACTIVATED LYMPHOCYTES-T IN DIABETIC NEPHROPATHY [J].
BENDING, JJ ;
LOBOYEO, A ;
VERGANI, D ;
VIBERTI, G .
DIABETES, 1988, 37 (05) :507-511
[3]
BOHREN KM, 1989, J BIOL CHEM, V264, P9547
[4]
BROWNLEE M, 1991, ANNU REV MED, V42, P159, DOI 10.1146/annurev.me.42.020191.001111
[5]
CHUNG S, 1989, J BIOL CHEM, V264, P14775
[6]
AMINOGUANIDINE, A NOVEL INHIBITOR OF NITRIC-OXIDE FORMATION, PREVENTS DIABETIC VASCULAR DYSFUNCTION [J].
CORBETT, JA ;
TILTON, RG ;
CHANG, K ;
HASAN, KS ;
IDO, Y ;
WANG, JL ;
SWEETLAND, MA ;
LANCASTER, JR ;
WILLIAMSON, JR ;
MCDANIEL, ML .
DIABETES, 1992, 41 (04) :552-556
[7]
NEUTROPHIL ALDOSE REDUCTASE-ACTIVITY AND ITS ASSOCIATION WITH ESTABLISHED DIABETIC MICROVASCULAR COMPLICATIONS [J].
DENT, MT ;
TEBBS, SE ;
GONZALEZ, AM ;
WARD, JD ;
WILSON, RM .
DIABETIC MEDICINE, 1991, 8 (05) :439-442
[8]
NEUTROPHIL ALDOSE REDUCTASE-ACTIVITY AS A POTENTIAL MARKER FOR NEUROPATHY AND CATARACT IN DIABETES [J].
DENT, MT ;
VEVES, A ;
TEBBS, SE ;
GONZALEZ, AM ;
MALIK, RA ;
BOULTON, AJM ;
WARD, JD ;
WILSON, RM .
DIABETIC MEDICINE, 1991, 8 (10) :911-916
[9]
DIMARIO U, 1986, CLIN EXP IMMUNOL, V65, P57
[10]
DVORNIK D, 1987, ALDOSE REDUCTASE INH, P7